Vitamins that may be helpful
L-carnitine is an amino acid needed to transport fats into the
mitochondria (the place in the cell where fats are turned into energy). Adequate energy
production is essential for normal heart function. Several studies using 1 gram of L-carnitine
two to three times per day showed an improvement in heart function and a reduction in symptoms
of angina.5 6 7
Coenzyme Q10 also contributes to the energy-making mechanisms of the heart. Angina
patients given 150 mg of coenzyme Q10 each day have experienced greater ability to exercise
without experiencing chest pain.8 This has been confirmed in independent
investigations.9
Low levels of antioxidant vitamins in the
blood, particularly vitamin E, are associated
with greater rates of angina.10 This is true even when smoking and other risk
factors for angina are taken into account. Early short-term studies using 300 IU
(International Units) per day of vitamin E could not find a beneficial action on
angina.11 A later study supplementing small amounts of vitamin E (50 IU per day)
for longer periods of time showed a minor benefit in people suffering angina.12
Those affected by variant angina have been found to have the greatest deficiency of vitamin E
compared with other angina patients.13
Nitroglycerin and similar drugs cause
dilation of arteries by interacting with nitric oxide, a potent stimulus for dilation. Nitric
oxide is made from arginine, a common amino
acid. Blood cells in people with angina are known to make insufficient nitric
oxide,14 which may in part be due to abnormalities of arginine metabolism. Taking 2
grams of arginine three times per day for as little as three days has improved the ability of
angina sufferers to exercise.15 Seven of ten people with severe angina improved
dramatically after taking 9 grams of arginine per day for three months in an uncontrolled
study.16 Detailed studies have investigated the mechanism of arginine and have
proven it operates by stimulating blood vessel dilation.17
N-acetyl cysteine (NAC) may improve the
effects of nitroglycerin in people with angina.18 People with unstable angina who
took 600 mg of NAC three times daily in combination with a nitroglycerin transdermal (skin)
patch for four months had significantly lower rates of subsequent heart attacks than did
people who used either therapy alone or placebo.19
Magnesium deficiency may be a contributing
factor for spasms that occur in coronary arteries, particularly in variant
angina.20 21 While studies have used injected magnesium to stop such
attacks effectively,22 23 it is unclear whether oral magnesium would be
effective in preventing or treating blood vessel spasms. One double-blind study of patients
with exercise-induced angina, however, showed that oral magnesium supplementation (365 mg
twice a day) for 6 months significantly reduced the incidence of exercise-induced chest pain,
compared with a placebo.24
In a controlled study, men with severe coronary heart disease were given an exercise test,
after which they took either 15 grams of
ribose or a placebo four times daily for three days. Compared with the initial test, men
taking ribose were able to exercise significantly longer before experiencing chest pain and
before abnormalities appeared on their electrocardiogram (ECG), but only the ECG changes were
significantly improved compared with those in the placebo group.25 Sports
supplement manufacturers recommend 1 to 10 grams per day of ribose, while heart disease
patients and people with rare enzyme deficiencies have been given up to 60 grams per day.
Bromelain has been reported in a
preliminary study to relieve angina. In that study, 600 people with cancer were receiving bromelain (400 to 1,000 mg per
day). Fourteen of those individuals had been suffering from angina. In all 14 cases, the
angina disappeared within 4 to 90 days after starting bromelain.26 However, as
there was no control group in the study, the possibility of a placebo effect cannot be ruled
out. Bromelain is known to prevent excessive stickiness of blood platelets,27 which
is believed to be one of the triggering factors for angina.
Fish oil, which contains the fatty acids
known as EPA and DHA, has been studied in the
treatment of angina. In some studies, enough fish oil to provide a total of about 3 grams of
EPA and 2 grams of DHA has reduced chest pain as well as the need for
nitroglycerin;28 other investigators could not confirm these findings.29
People who take fish oil may also need to take
vitamin E to protect the oil from undergoing potentially damaging oxidation in the
body.30 It is not known how much vitamin E is needed to prevent such oxidation; the
amount required would presumably depend on the amount of fish oil used. In one study, 300 IU
of vitamin E per day prevented oxidation damage in individuals taking 6 grams of fish oil per
day.31
Are there any side effects or interactions?
Refer to the individual supplement for information about any side effects or interactions.
1. LaCroix AZ, Mead LA, Liang KY, et al. Coffee consumption and the
incidence of coronary heart disease. N Engl J Med 1986;315:977–82.
2. Deanfield J, Wright C, Krikler S, et al. Cigarette smoking and the
treatment of angina with propranolol, atenolol, and nifedipine. N Engl J Med
1984;310:951–4.
3. Glantz SA, Parmley WW. Passive smoking and heart disease.
JAMA 1995;273:1047–53 [review].
4. Todd IC, Ballantyne D. Antianginal efficacy of exercise training: A
comparison with beta blockade. Br Heart J 1990;64:14–9.
5. Cherchi A, Lai C, Angelino F, et al. Effects of L-carnitine on
exercise tolerance in chronic stable angina: A multicenter, double-blind, randomized,
placebo-controlled crossover study. Int J Clin Pharmacol Ther Toxicol
1985;23:569–72.
6. Canale C, Terrachini V, Biagini A, et al. Bicycle ergometer and
echocardiographic study in healthy subjects and patients with angina pectoris after
administration of L-carnitine: Semiautomatic computerized analysis of M-mode tracing. Int
J Clin Pharmacol Ther Toxicol 1988;26:221–4.
7. Cacciatore L, Cerio R, et al. The therapeutic effect of L-carnitine in
patients with exercise-induced stable angina: A controlled study. Drugs Exp Clin Res
1991;17:225–35.
8. Kamikawa T, Kobayashi A, Yamashita T, et al. Effects of coenzyme Q10
on exercise tolerance in chronic stable angina pectoris. Am J Cardiol
1985;56:247.
9. Mortensen SA. Perspectives on therapy of cardiovascular diseases with
coenzyme Q10 (ubiquinone). Clin Investig 1993;71:S116–23 [review].
10. Riemersma RA, Wood DA, Macintyre CC, et al. Risk of angina pectoris
and plasma concentrations of vitamins A, C, and E and carotene. Lancet
1991;337:1–5.
11. Rinzler SH, Bakst H, Benjamin ZH, et al. Failure of alpha-tocopherol
to influence chest pain in patients with heart disease. Circulation
1950;1:288–90.
12. Rapola RM, Virtamo J, Haukka JK, et al. Effect of vitamin E and beta
carotene on the incidence of angina pectoris. A randomized, double-blind, controlled trial.
JAMA 1996;275:693–8.
13. Miwa K, Miyagi Y, Igawa A, et al. Vitamin E deficiency in variant
angina. Circulation 1996;94:14–8.
14. Mollace V, Romeo F, Martuscelli E, et al. Low formation of nitric
oxide in polymorphonuclear cells in unstable angina pectoris. Am J Cardiol
1994;74:65–8.
15. Ceremuzynski L, Chamiec T, Herbaczynska-Cedro K. Effect of
supplemental oral L-arginine on exercise capacity in patients with stable angina pectoris.
Am J Cardiol 1997;80:331–3.
16. Blum A, Porat R, Rosenschein U, et al. Clinical and inflammatory
effects of dietary L-arginine in patients with intractable angina pectoris. Am J
Cardiol 1999;83:1488–90.
17. Egashira K, Hirooka Y, Kuga T, et al. Effects of L-arginine
supplementation on endothelium-dependent coronary vasodilation in patients with angina
pectoris and normal coronary arteriograms. Circulation 1996;94:130–4.
18. Marchetti G, Lodola E, Licciardello L, Colombo A. Use of
N-acetylcysteine in the management of coronary artery diseases. Cardiologia
1999;44:633–7.
19. Ardissino D, Merlini PA, Savonitto S, et al. Effect of transdermal
nitroglycerin or N-acetylcysteine, or both, in the long-term treatment of unstable angina
pectoris. J Am Coll Cardiol 1997;29:941–7.
20. Turlapaty P, Altura B. Magnesium deficiency produces spasms of
coronary arteries: Relationship to etiology of sudden death ischemic heart disease.
Science 1980;208:199–200.
21. Goto K, Yasue H, Okumura K, et al. Magnesium deficiency detected by
intravenous loading test in variant angina pectoris. Am J Cardiol
1990;65:709–12.
22. Cohen L, Kitzes R. Magnesium sulfate in the treatment of variant
angina. Magnesium 1984;3:46–9.
23. Cohen L, Kitzes R. Prompt termination and/or prevention of
cold-pressor-stimulus-induced vasoconstriction of different vascular beds by magnesium sulfate
in patients with Prinzmetal’s angina. Magnesium 1986;5:144–9.
24. Shechter M, Bairey Merz CN, et al. Effects of oral magnesium therapy
on exercise tolerance, exercise-induced chest pain, and quality of life in patients with
coronary artery disease. Am J Cardiol 2003;91:517–21.
25. Pliml W, von Arnim T, Stablein A, et al. Effects of ribose on
exercise-induced ischemia in stable coronary artery disease. Lancet
1992;340:507–10.
26. Nieper H. Effect of bromelain on coronary heart diseases and angina
pectoris. J Int Acad Prev Med 1976;3(2):62–3.
27. Heinicke R, van der Wal L, Yokoyama M. Effect of bromelain (Ananase)
on human platelet aggregation. Experientia 1972;28:844–5.
28. Saynor R, Verel D, Gillott T. The long-term effect of dietary
supplementation with fish lipid concentrate on serum lipids, bleeding time, platelets and
angina. Atherosclerosis 1984;50:3–10.
29. Mehta JL, Lopez LM, Lawson D, et al. Dietary supplementation with
omega-3 polyunsaturated fatty acids in patients with stable coronary heart disease. Effects on
indices of platelet and neutrophil function and exercise performance. Am J Med
1988;84:45–52.
30. Wander RC, Du SH, Ketchum SO, Rowe KE. Alpha-tocopherol influences in
vivo indices of lipid peroxidation in postmenopausal women given fish oil. J Nutr
1996;126:643–52.
31. Oostenbrug GS, Mensink RP, Hornstra G. A moderate in vivo vitamin E
supplement counteracts the fish-oil-induced increase in in vitro oxidation of human
low-density lipoproteins. Am J Clin Nutr 1993;57:827S.
32. Hanack T, Bruckel MH. The treatment of mild stable forms of angina
pectoris using Crataegutt® novo. Therapiewoche 1983;33:4331–3 [in
German].
33. Conn JJ, Kisane RW, Koons RA, Clark TE. Treatment of angina pectoris
with khellin. Ann Intern Med 1952;36:1173–8.
34. Osher HL, Katz KH, Wagner DJ. Khellin in the treatment of angina
pectoris. New Engl J Med 1951;244:315–21.
35. Ballegaard S, Pedersen F, Pietersen A, et al. Effects of acupuncture
in moderate, stable angina pectoris: a controlled study. J Intern Med
1990;227:25–30.
36. Ballegaard S, Karpatschoff B, Holck JA, et al. Acupuncture in angina
pectoris: do psychosocial and neurophysiological factors relate to the effect? Acupunct
Electrother Res 1995;20:101–16.
37. Ballegaard S, Norrelund S, Smith DF. Cost-benefit of combined use of
acupuncture, Shiatsu and lifestyle adjustment for treatment of patients with severe angina
pectoris. Acupunct Electrother Res 1996;21:187–97.
38. Ballegaard S, Jensen G, Pedersen F, Nissen VH. Acupuncture in severe,
stable angina pectoris: a randomized trial. Acta Med Scand 1986;220:307–13.
39. Richter A, Herlitz J, Hjalmarson A. Effect of acupuncture in patients
with angina pectoris. Eur Heart J 1991;12:175–8.
40. Cunningham D, Brown S, Kaski JC. Effects of transcendental meditation
on symptoms and electrocardiographic changes in patients with Cardiac Syndrome X. Am J of
Cardiology 2000;85:653–5.
41. Burchett GC. Somatic manifestations of ischemic heart disease.
Osteopathic Annals 1976;4:373–5.
42. Nicholas AS, DeBias, et al. A somatic component to myocardial
infarction. Br Med J 1985;291:13–7.
43. Beal MC, Kleiber GE. Somatic dysfunction as a predictor of coronary
artery disease. J Am Osteopath Assoc 1985; 85:70–5.
44. Beal MC Palpatory testing for somatic dysfunction in patients with
cardiovascular disease. J Am Osteopath Assoc 1983;82:73–82.
45. Cox JM, Gorbis S, Dick LM, et al. Palpable musculoskeletal findings
in coronary artery disease: results of a double blind study. J Am Osteopath Assoc
1983;82(11)832–6.
46. McGuiness J, Vicenzino B, Wright A. The influence of a cervical
mobilization technique on respiratory and cardiovascular function. Man Ther
1997;2:216–20.
47. Vicenzino B, Cartwright T, Collins D. Cardiovascular and respiratory
changes produced by lateral glide mobilization of the cervical spine. Man Ther 1998
3(2):67–71.
48. Nansel D, Jansen R, Cremata E, et al. Effects of cervical adjustments
on lateral-flexion passive end-range asymmetry and on blood pressure, heart rate and plasma
catecholamine levels. J Manip Physiol Ther 1991;14:450–6.